Specificities of clinical research in radiotherapy.

{"article_title":"Specificities of clinical research in radiotherapy.","author":"Hennequin C, Azria D, Blanchard P, Cr\u00e9hange G, Deutsch \u00c9, Lisbona A, Moyal \u00c9, Pasquier D, Roca L, Supiot S, Giraud P","journal_title":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","issn":"1769-6658","isbn":"","publication_date":"2022-02-01","volume":"26","issue":"1-Feb","first_page":"104","page_count":"","accession_number":"34953712","doi":"10.1016\/j.canrad.2021.11.011","publisher":"Elsevier","doctype":"Journal Article","subjects":"France; Biomedical Research economics; Clinical Trials as Topic methods; Radiation Oncology; Radiotherapy standards; Research Design; France; Health Physics; Humans; Patient Selection; Progression-Free Survival; Quality Control; Quality of Life; Radiotherapy Dosage; Research Support as Topic","interest_area":["Oncology"," Radiology"],"abstract":"The aim of this review is to present the specificities of clinical research in radiation oncology. Objectives are similar to all research in oncology: to improve the efficacy and to decrease toxic effects. Phase III trials remain the main methodology to demonstrate an improvement in efficiency, but phase I-II and registers are also important tools to validate an improvement in the therapeutic index with new technologies. In this article we discuss the special features of end-points, selection of population, and design for radiation oncology clinical trials. Quality control of delivered treatments is an important component of these protocols. Financial issues are also discussed, in the particular context of France. Copyright \u00a9 2021. Published by Elsevier Masson SAS.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34953712","isPdfLink":false,"isSAML":false,"an":"34953712","number_other":"","type_pub":"","issn_electronic":"1769-6658","languages":"English","language":"eng","date_entry":"Date Created: 20211226 Date Completed: 20220217 Latest Revision: 20220217","date_update":"20240104","titleSource":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2022 Feb-Apr; Vol. 26 (1-2), pp. 104-107. Date of Electronic Publication: 2021 Dec 23.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2022-02-01","description":"The aim of this review is to present the specificities of clinical research in radiation oncology. Objectives are similar to all research in oncology: to improve the efficacy and to decrease toxic effects. Phase III trials remain the main methodology to demonstrate an improvement in efficiency, but phase I-II and registers are also important tools to validate an improvement in the therapeutic index with new technologies. In this article we discuss the special features of end-points, selection of population, and design for radiation oncology clinical trials. Quality control of delivered treatments is an important component of these protocols. Financial issues are also discussed, in the particular context of France.<br \/> (Copyright © 2021. Published by Elsevier Masson SAS.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=34953712&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Hennequin C, Azria D, Blanchard P, Cr\u00e9hange G, Deutsch \u00c9, Lisbona A, Moyal \u00c9, Pasquier D, Roca L, Supiot S, Giraud P"}